Transaction

Clearwater advises Lexon on refinancing to aid growth strategy

Transaction

Lexon raised finance to support growth

Refinancing

€71m

Role

Adviser to Lexon on refinancing to aid its growth strategy

Sector

Healthcare

Region

United Kingdom

Clearwater has advised Lexon, a leading supplier to independent pharmacies across the UK on a multi-million pound refinancing deal which will help the business reach its growth targets in 2022 and beyond.

Redditch-based Lexon, which also has distribution centres in Leeds, Durham and Dublin, supports thousands of independent pharmacies and was established in 1995.

The £60m (€71m) asset backed lending facility with HSBC UK will support the business in its growth strategy across the board, including capital expenditure in areas such as new tech and facilities to drive business development.

Lexon, a family owned and managed business, also operates its own range of pharmacies - Knights Pharmacies - and a generic drug manufacturer - Key Pharmaceuticals. Staff figures total more than 1,200 across the operations.

Over the past 24 months, the company has assisted the frontline fight against COVID-19, working with its pharmacy partners, as well as hosting multiple vaccination centres across the country.

Its most recent turnover was £240m (€284m).

image 112

We are delighted to have completed this deal - it will help Lexon grow and continue to support independent pharmacies across the UK, as we have done for many years, in fresh and exciting ways. We are looking forward to what the future holds and would like to thank Clearwater for their support, as well as the commitment and hard work of the Lexon family for getting us to this point.

Nimesh Sodha, Director, Lexon
image 112

It was a pleasure to have supported Lexon in securing a flexible funding package. The facility will allow management to optimise its day-to-day funding whilst providing additional headroom for growth. Lexon already holds a great position in the market and this facility will allow it to continue to develop this. We’d like to wish the team all the best.

Joe Dyke, Partner, Clearwater

Advisers

Transactions